KRAS is one of the most frequently mutated oncogenes in human cancer, acting as a molecular switch that locks cells into a growth-promoting state. In most colorectal cancers, the same handful of canonical KRAS variants appear again and again, particularly substitutions at codons 12 and 13 that interfere with the protein’s ability to switch itself off. These canonical mutations are potent drivers, and their recurrence has traditionally been read as evidence of strong positive selection. Yet in hypermutant cancers, tumours burdened with extraordinarily high mutation loads, a strikingly different picture emerges. Atypical KRAS variants, mutations at unusual positions or of unusual types, appear far more often than their oncogenic strength would seem to justify.

This paradox has troubled cancer evolutionary biologists for years. If a weak driver confers less of a growth advantage than a canonical one, and if both are available to a tumour, conventional evolutionary logic predicts that the stronger driver should prevail and outcompete the weaker alternative. The persistence of weak drivers in hypermutant tumours therefore demanded an explanation. One intuitive hypothesis was that these tumours might somehow favour weak drivers through differential selection, perhaps because the cellular context of a hypermutant cancer changes what mutations are useful. Nicholson and Tomlinson set out to test whether such an appeal to altered selection was actually necessary.

Their approach was to build mathematical models of tumour evolution that track the appearance and expansion of driver mutations over the course of a cancer’s development. The models incorporate the basic currency of cancer genetics: cell divisions, mutation rates, the probability that a given division produces a driver mutation, and the selective growth advantage each driver confers. By varying these parameters, the researchers could ask under what conditions weak drivers would be expected to dominate the final tumour population. The answer they found was deceptively simple. When the mutation rate per cell division is elevated, further driver events occur so rapidly that the dynamics of tumour evolution are fundamentally altered, and weak drivers can rise to dominance even in direct competition with stronger alternatives.

The intuition behind this result is worth unpacking. In a tumour with a normal mutation rate, driver events are rare. A cell that acquires a strong driver mutation has time to expand into a large clone before the next driver arises, so the strongest available driver tends to sweep through the population. But in a hypermutant tumour, driver events arrive in quick succession. A cell carrying a weak driver may acquire additional driver mutations before any stronger competitor has had the chance to establish itself. The weak driver effectively gets a head start, and the sheer speed of subsequent mutation means that the tumour’s evolutionary trajectory is shaped more by the order and timing of events than by the fine ranking of selective advantages. Selection still matters, but the race is run so fast that the starting position can matter more than the finishing speed.

The researchers also found that this effect can be amplified by mutational biases, systematic tendencies of a mutational process to produce certain nucleotide changes in certain sequence contexts rather than others. Mutational processes are not random. Ultraviolet light, tobacco smoke, defective DNA repair enzymes and defective proofreading polymerases each leave characteristic fingerprints in the genome, preferentially mutating particular bases in particular neighbourhoods. If a hypermutational process happens to target the sequence contexts required for atypical KRAS variants, while rarely generating the contexts needed for canonical ones, then the supply of candidate weak drivers is inflated relative to the supply of strong ones. Combined with an elevated mutation rate, this bias can be sufficient to make atypical drivers the dominant species in the tumour.

To test whether this theoretical framework matched reality, the team focused on a specific and clinically important example: colorectal cancers with mutations in POLE, the gene encoding the proofreading domain of DNA polymerase epsilon. When this proofreading function fails, the enzyme makes copying errors at a greatly elevated rate, producing some of the highest mutation burdens seen in any human cancer. Nicholson and Tomlinson quantified the mutation bias of the POLE-mutant process for a range of KRAS driver variants, comparing the sequence contexts generated under POLE deficiency with those generated under non-hypermutant mutational processes. They found that the combination of the POLE-specific bias and the elevated mutation rate was sufficient to explain the observed enrichment of atypical KRAS drivers in these tumours. No special selective regime needed to be invoked.

The model’s predictive power extended beyond POLE-mutant cancers. Mismatch repair deficient colorectal cancers, another hypermutant class arising from a different DNA repair defect, also show an elevated prevalence of atypical KRAS drivers. When the researchers applied their model to this setting, its predictions were consistent with the observed variant frequencies. This is a notable result because POLE deficiency and mismatch repair deficiency generate mutations through different chemical mechanisms with different sequence biases, yet both produce the same qualitative outcome: weak, atypical drivers rising to prominence. The convergence suggests that the underlying principle, hypermutation reshaping the balance between mutation supply and selection, is general rather than specific to one repair pathway.

The broader implication of the study is a clarification of how mutation and selection interact during tumorigenesis. Textbook accounts of cancer evolution often treat driver mutations as the winners of a pure selection contest, with the fittest mutations sweeping to fixation. This work shows that in hypermutant tumours, the mutational process itself can act as a filter that determines which drivers are even available in meaningful numbers, and that the tempo of mutation can override fine-grained differences in selective advantage. Differential selection across cancer types need not be invoked to explain why different tumour classes carry different driver repertoires. The variation may simply be a consequence of how fast each tumour mutates and what kinds of mutations its particular defect produces.

There are also practical consequences for precision oncology. Atypical KRAS variants have historically been poorly characterised compared with their canonical counterparts, and their functional consequences are often uncertain. If many of these variants arise as passengers or weak drivers propelled by hypermutation rather than as potent oncogenic signals, this has implications for how they are interpreted in clinical sequencing reports and for which variants become targets of drug development. More broadly, the study adds to a growing appreciation that mutation rate is not merely a background parameter of cancer evolution but an active force that shapes which evolutionary paths tumours take. Understanding the interplay between mutational processes and selection, the authors conclude, is essential for explaining the diversity of driver mutations observed across human cancers, and mathematical modelling of the kind employed here offers a way to disentangle these forces that raw genomic data alone cannot provide.

Subject of Research: Evolutionary dynamics of weak KRAS driver mutations in hypermutant colorectal cancers

Article Title: Hyper-mutational processes provide a head-start for weak cancer drivers: Explaining atypical KRAS variants

Article References: Nicholson, M. D., & Tomlinson, I. (2026). Hyper-mutational processes provide a head-start for weak cancer drivers: Explaining atypical KRAS variants. PLOS Computational Biology, 22(10), e1014858. https://doi.org/10.1371/journal.pcbi.1014858

Image Credits: AI Generated

DOI: 10.1371/journal.pcbi.1014858

Keywords: KRAS, hypermutation, POLE, colorectal cancer, mathematical modelling, cancer evolution, driver mutations, mismatch repair deficiency, mutational bias, PLOS Computational Biology, tumorigenesis, selection

The team, led by Nico Appold, Timon Citak, Auguste Palm and Jona Kayser, built a microbial therapy-mimicry assay around the budding yeast Saccharomyces cerevisiae. Populations were initiated from single, genetically tailored cells placed in a high-throughput arrayed colony assay, where each founder cell expanded into a compact, range-expanding colony. To generate a continual supply of trackable resistant mutants, the researchers engineered a stochastic, irreversible synthetic mutation system based on a hierarchical dual-recombinase switch. In the unmutated state, cells are thermosensitive: they proliferate at 30 degrees Celsius but arrest at 35 degrees. Upon switching, cells become thermoresistant and simultaneously change fluorescence colour, allowing resistant lineages to be identified and followed throughout colony growth. Treatment itself is delivered through programmable temperature shifts, giving the experimenters precise control over therapy onset, duration and pause.

Combining this assay with multi-day time-lapse fluorescence microscopy and automated temperature control, the researchers recorded population histories for up to 160 hours, spanning more than 100 generations. A custom image-analysis pipeline using machine learning-based segmentation extracted colony- and clone-level dynamics from the raw imaging data. Radial kymographs, which trace population structure along the direction of expansion, revealed two qualitatively distinct fates for resistant clones. Some escaped confinement as continually growing domes at the colony edge, but most remained trapped within the population bulk. This baseline phenomenology set the stage for the central question: what determines whether a bulk-born mutant escapes or stays confined?

Under continuous therapy, the answer proved to be strikingly spatial. Although the temperature shift was spatially homogeneous, mutant expansion showed pronounced spatiotemporal structure. The time at which a resistant mutant was first detected correlated strongly with its distance from the colony front, indicating that mutant growth was gated by a spatially varying growth potential within the colony. Individual mutant trajectories crept towards the colony edge until permanent escape occurred, and mutants originating further inward sometimes remained confined when a more forward lineage occupied the advancing front. At the colony level, this created a finite time window after therapy onset during which no mutant had yet escaped; as therapy continued, the cumulative number of escaped mutants rose steadily.

The existence of this delay suggested a therapeutic lever. If treatment were paused before any mutant reached the edge, the resumption of sensitive growth might re-establish a competitive barrier at the front. The researchers tested this with a 14-hour therapy pulse followed by a treatment holiday. Strikingly, many mutants that had expanded during the pulse stalled and remained confined within the colony bulk, with re-confinement often preceding the full recovery of sensitive expansion. Systematically varying pulse duration showed that shortening treatment strongly enhanced confinement: for pulses shorter than six hours, resistance escape was almost completely suppressed. The maximum safe pulse length proved more restrictive than continuous-therapy trajectories alone would suggest, because mutants continue advancing during the post-pulse regrowth lag.

To explain these observations mechanistically, the team constructed a stochastic simulation framework, a mechanistically minimal digital twin in which nutrient dynamics are directly accessible. Space is discretized into a two-dimensional grid of demes containing sensitive and resistant cells that proliferate at nutrient-dependent rates and disperse through growth-driven spreading. Competition is mediated solely through a shared, freely diffusing and consumable nutrient field, with no explicit local carrying capacity. Therapy is implemented as a modulation of sensitive growth that captures experimentally observed response kinetics, including on-delays and post-treatment lags. Despite its minimal structure, the model qualitatively reproduced the key experimental dynamics: bulk-born mutants released under therapy, and re-confinement when treatment pauses allowed sensitive growth to rebound.

The digital twin revealed the underlying resource logic. In a range-expanding population, growth and nutrient consumption generate a nutrient gradient along the expansion direction, and the advancing front continuously couples the colony edge to the high-nutrient side of this gradient. Under continuous therapy, suppressed sensitive growth reduces nutrient consumption, allowing nutrients to penetrate inward and expanding the growth-permitting region into the bulk. This releases previously confined resistant mutants and ultimately enables them to reach and escape at the colony edge. Pausing therapy reverses the process: renewed sensitive growth restores nutrient depletion in the bulk and reforms a competitive barrier of sensitive cells at the front, restoring spatial confinement.

With this mechanism in hand, the researchers scanned a large space of intermittent schedules, varying the durations of therapy-on and therapy-off intervals. Performance was quantified by time to progression, the time required for colony area to exceed a predefined threshold. Across schedule space, time to progression exhibited a pronounced ridge of optimal schedules separating two modes of failure: sensitive-dominated progression under too little treatment and resistant-dominated progression under too much. A sharp switch in the resistant fraction occurred near the optimum, which the authors describe as a dynamic phase-transition-like boundary in schedule space. Beyond the critical pulse length, therapy depresses front growth strongly enough that recovery during each pause is incomplete, producing a ratchet-like drift that progressively weakens confinement until resistant clones escape.

Guided by the simulations, the team tested the predicted sweet spot experimentally using pulse durations of four, 6.5 and nine hours with 18-hour pauses. The experiments confirmed a local optimum: time to progression peaked at 6.5-hour pulses, which significantly outperformed continuous therapy and both adjacent schedules, and the resistant fraction rose sharply near the transition. The 9-hour schedule reproduced the model-predicted cumulative decline in sensitive growth and surge in mutant escapes. As a proof of principle, the researchers also ran an adaptive therapy experiment in which treatment intervals were adjusted in real time based on measured growth rebound rather than fixed intervals. This closed-loop strategy slowed overall growth more than any fixed schedule, typically delaying progression beyond the experimental runtime, although resistant-population dynamics were more variable.

The study establishes resource-mediated spatial confinement as a central organizing principle of resistance evolution and offers a mechanistic foundation for spatially informed, evolution-based therapies. The authors suggest that growth rebound could serve as a clinically accessible measure of confinement potential, and that poorly vascularized tumours with steep resource gradients may be ideal candidates for such approaches, potentially enhanced by angiogenesis-targeting drugs. The findings may also explain why recent clinical trials of intermittent therapy failed to improve progression-free survival: the therapeutic sweet spot is narrow, and hitting it requires accounting for spatial resource dynamics that mean-field models ignore. The researchers caution that their yeast assay is deliberately reductionist, and that testing confinement-and-release dynamics in three-dimensional cancer organoids and matrix-producing biofilms will be essential before drawing clinical conclusions. Still, the message is clear: whether therapy fails may hinge on whether treatment shifts the resource gradient long enough for bulk-born mutants to permanently escape confinement.

Subject of Research: Spatial resource dynamics governing the emergence and escape of therapy-resistant mutants in structured microbial populations

Article Title: A microbial therapy-mimicry assay shows how spatial resource dynamics control resistance escape

Article References: A microbial therapy-mimicry assay shows how spatial resource dynamics control resistance escape. (n.d.). https://doi.org/10.1038/s41559-026-03178-z

Image Credits: AI Generated

DOI: 10.1038/s41559-026-03178-z

Keywords: therapy resistance, spatial evolution, nutrient gradients, intermittent therapy, adaptive therapy, yeast colonies, digital twin, biofilms, cancer evolution, experimental evolution, phase transition, range expansion

The concept rests on a principle borrowed from evolutionary ecology. When cancer cells evolve resistance to a first-line drug, the molecular machinery they deploy often carries hidden costs or collateral vulnerabilities. A collateral sensitivity arises when adaptation to one drug increases susceptibility to another. The researchers hypothesized that if a second drug could exploit such a vulnerability, then applying selective pressure with chemotherapy would actively steer the tumor population into a corner: cells that resist chemotherapy become exquisitely sensitive to the second agent, leaving them nowhere evolutionarily to hide. This is the double-bind, a strategy first theorized in mathematical oncology but rarely demonstrated with a concrete drug pair and a validated treatment schedule.

To find such a pair, the team, led by Rena Emond of City of Hope and Jeffrey West of the Moffitt Cancer Center, worked with two ER+ breast cancer cell lines, MCF-7 and T-47D. Over six to eight months, they evolved sublines resistant to two common chemotherapies, paclitaxel and doxorubicin, by exposing cells to weekly pulses of each drug. They then screened thirty-seven candidate compounds, spanning FDA-approved oncology drugs, agents tested in clinical trials, and inhibitors of pathways linked to resistance. The screen measured whether each candidate preferentially killed resistant cells relative to their sensitive parents. Disulfiram, an inhibitor of aldehyde dehydrogenase, stood out: across all four chemotherapy-resistant line pairs, it showed dose-dependent toxicity that spared the sensitive parental cells, exactly the asymmetry a double-bind requires.

With disulfiram identified, the next question was whether combining it with chemotherapy produced true synergy, mere additivity, or antagonism. The researchers ran full checkerboard dose-response assays on both sensitive and resistant lines and analyzed the results with the MuSyC framework, which separates synergy into two components: synergistic potency, a shift in the half-maximal effective concentration, and synergistic efficacy, an increase in the maximum killing achieved at high doses of both drugs. The results were nuanced. In treatment-naive cells, the combination was largely neutral, meaning the two drugs acted additively rather than synergistically. In most resistant lines the additivity held, with one notable exception: doxorubicin-resistant MCF-7 cells displayed genuine synergistic potency with the combination. Importantly, antagonism was rarely observed, and the high-dose combination achieved maximal killing across every cell line and resistance background tested.

One curious finding emerged from the dose-response curves. Disulfiram alone behaved non-monotonically: intermediate doses killed more cells than the highest doses, producing a paradoxical dip in efficacy at high concentrations. When chemotherapy was added, this instability vanished, and the combination curve became smoothly dose-dependent. The authors suggest chemotherapy stabilizes disulfiram’s drug effect, an observation that underscores how combination contexts can rescue drugs whose monotherapy behavior is unpredictable. The team also notes that even additive combinations can be clinically valuable, a point increasingly recognized as trials of supposedly synergistic combinations often deliver benefits explainable by simple independent drug action.

Drug-drug interactions, however, tell only half the story. Tumors are ecosystems in which sensitive and resistant cells compete, cooperate, and modulate each other’s growth. To capture these dynamics, the researchers turned to the evolutionary game assay, a technique that quantifies frequency-dependent growth rates. They fluorescently labeled sensitive cells with one protein and resistant cells with another, then grew them as three-dimensional spheroids at initial resistant fractions of zero, twenty-five, fifty, seventy-five, and one hundred percent. Under untreated conditions, sensitive cells grew faster across all mixtures, revealing a fitness cost to resistance. Under chemotherapy, resistant cells held their advantage as expected. Under disulfiram, the picture flipped: resistant cells lost fitness to a far greater degree than sensitive ones, confirming the collateral sensitivity in a competitive, three-dimensional setting that more closely mimics the tumor microenvironment than flat culture dishes.

From these experiments the team built a game-theoretic mathematical model. Each cell type’s growth rate is described as a linear function of the population’s composition, yielding a four-parameter payoff matrix. Two derived quantities, the invasion fitnesses of sensitive and resistant cells when rare, determine the selection dynamics: whether sensitive cells dominate, resistant cells take over, the two coexist, or the system is bistable. The model also defines an overall tumor fitness, the long-term growth rate of the whole spheroid once selection reaches equilibrium. The critical prediction was unambiguous: continuous combination therapy with chemotherapy and a high dose of disulfiram drove tumor fitness to its most negative value, meaning the entire population, sensitive and resistant alike, would shrink rather than merely shift in composition.

The model then confronted a practical clinical question: should the two drugs be given together, or sequentially? Because the double-bind depends on resistance to the first drug, one might reasonably argue for chemotherapy first and disulfiram later. The team simulated alternating schedules with fast weekly and slower biweekly switching, always beginning with chemotherapy since disulfiram performs best once resistance has been selected. Across all parameterizations, the simulations predicted that combination therapy would outperform every sequential regimen. The researchers then tested this prediction directly in their spheroid system, treating mixed populations with twenty-five nanomolar doxorubicin and five hundred nanomolar disulfiram either continuously or in alternating schedules. The experiments confirmed the mathematics: combination treatment suppressed total cell count more effectively than any sequential strategy, across both cell lines and all initial resistant fractions. Interestingly, in MCF-7 cultures, leading a sequential schedule with disulfiram controlled growth better than leading with chemotherapy, but neither alternating approach matched the continuous combination.

The choice of disulfiram carries practical appeal beyond its evolutionary credentials. As an FDA-approved drug with decades of safety data, it can be repurposed without the lengthy development timeline of a novel molecule. Clinical trials have already explored disulfiram combinations in metastatic pancreatic cancer, treatment-refractory sarcoma, and recurrent glioblastoma, though the glioblastoma trial showed no significant survival benefit. Preclinical work suggests multiple mechanisms by which disulfiram might strike at chemo-resistant cells: it inhibits PI3K signaling, blocks ABC drug efflux pumps that drive multidrug resistance, suppresses NF-kB and epithelial-mesenchymal transition, undermines breast cancer stem cell self-renewal, and its copper-dependent metabolite induces p53-mediated apoptotic cell death. The present study did not pinpoint which of these mechanisms underlies the observed collateral sensitivity, and the authors flag mechanistic dissection as a priority for future work.

The researchers are careful about scope. These results come from cell lines and spheroids, not patients, and translating the double-bind into the clinic will require in vivo studies to establish optimal dosing, timing, and toxicity, particularly since disulfiram is unlikely to be administered alone and may behave differently in copper-containing combinations. Still, the study delivers something rarer than another drug pair: a validated, quantitative framework that integrates drug screening, evolutionary game assays, and mathematical modeling to predict which treatment schedule best suppresses resistance before a single patient is treated. If the evolutionary double-bind holds up in animal models and trials, the strategy could reframe how oncologists think about drug resistance, not as an inevitable failure of chemotherapy, but as a predictable vulnerability waiting to be exploited.

Subject of Research: Evolutionary double-bind combination therapy with disulfiram and chemotherapy to suppress drug resistance in ER+ breast cancer

Article Title: A novel combination therapy for ER+ breast cancer suppresses drug resistance via an evolutionary double-bind

Article References: Emond, R., West, J., Grolmusz, V. K., Cosgrove, P. A., Nath, A., Anderson, A. R. A., & Bild, A. H. (2026). A novel combination therapy for ER+ breast cancer suppresses drug resistance via an evolutionary double-bind. Molecular Systems Biology, 22(7), 1070-1096. https://doi.org/10.1038/s44320-026-00191-z

Image Credits: AI Generated

DOI: 10.1038/s44320-026-00191-z

Keywords: ER+ breast cancer, drug resistance, disulfiram, chemotherapy, collateral sensitivity, evolutionary game theory, combination therapy, drug repurposing, mathematical modeling, spheroids, Molecular Systems Biology, cancer evolution